Latest News - Page 3 of 44 - Oklahoma Society of Clinical Oncology

Takeda Oncology changes name of their patient support program

Takeda Oncology announces that the name of their patient support program has changed from Takeda Oncology 1Point to Takeda Oncology Here2Assist™ effective May 18, 2020. Please note that only the name is changing. Patients and providers will continue to have the same high level of comprehensive, personalized support. Please review the important details regarding the change here:  Takeda […]

Read More

CMS Releases Additional Waivers for Hospitals and Other Facilities

CMS continues to release waivers for the health care community that provide the flexibilities needed to take care of patients during the COVID-19 Public Health Emergency (PHE). CMS recently provided additional blanket waivers for the duration of the PHE. For more information, see Emergency Declaration Blanket Waivers.

Read More

Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14 • Tabrecta (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14)1 • ~4,000-5,000 patients are diagnosed with METex14 metastatic […]

Read More

Merck announces that ONTRUZANT® (trastuzumab-dttb) for injection, for intravenous use 21 mg/mL, a biosimilar* to Herceptin® (trastuzumab), is available through specialty distributors and wholesalers.

Merck Sharp & Dohme Corp. (“Merck”), a subsidiary of Merck & Co., Inc., is pleased to announce that ONTRUZANT® (trastuzumab-dttb) for injection, for intravenous use 21 mg/mL, a biosimilar* to Herceptin® (trastuzumab), is available through specialty distributors and wholesalers. Please contact your specialty distributor or wholesaler to confirm product availability. Before prescribing ONTRUZANT, please read the Prescribing Information, including the […]

Read More

Seattle Genetics announces approval of TUKYSA by the U.S. Food and Drug Administration (FDA).

TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. We look forward to sharing the efficacy and safety data from the HER2CLIMB trial as […]

Read More

U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy.1 The approval is based on results […]

Read More

FDA announces approval of KEYTRUDA® for additional treatments.

Merck is pleased to announce that KEYTRUDA® (pembrolizumab) has been approved by the FDA for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ·    PD-L1 diagnostic testing is not required prior to […]

Read More

Taiho Oncology announces a new patient assistance program

Taiho Oncology announced that is offering a new patient assistance program where eligible patients pay $0 per treatment plan.  Patients who are reimbursed under Medicaid, a Medicare drug benefit program, Tricare, or other state or federal programs are not eligible.  To determine patient eligibility, go to or call: TaihoOncologyCopay.com or phone (844) TAIHO-4U (844-824-4648).

Read More

LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LYNPARZA for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of […]

Read More

FDA approves ENHERTU® for treatment of adult patients with unresectable or metastatic Her2 positive breast cancer.

Daiichi Sankyo and AstraZeneca announced that the US Food and Drug Administration (FDA) approved ENHERTU® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. This indication is approved under accelerated approval based on tumor response […]

Read More